» Articles » PMID: 37212072

Nomogram for Early Prediction of Parkinson's Disease Based on MicroRNA Profiles and Clinical Variables

Overview
Publisher Sage Publications
Specialty Neurology
Date 2023 May 22
PMID 37212072
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Few efficient and simple models for the early prediction of Parkinson's disease (PD) exists.

Objective: To develop and validate a novel nomogram for early identification of PD by incorporating microRNA (miRNA) expression profiles and clinical indicators.

Methods: Expression levels of blood-based miRNAs and clinical variables from 1,284 individuals were downloaded from the Parkinson's Progression Marker Initiative database on June 1, 2022. Initially, the generalized estimating equation was used to screen candidate biomarkers of PD progression in the discovery phase. Then, the elastic net model was utilized for variable selection and a logistics regression model was constructed to establish a nomogram. Additionally, the receiver operating characteristic (ROC) curves, decision curve analysis (DCA), and calibration curves were utilized to evaluate the performance of the nomogram.

Results: An accurate and externally validated nomogram was constructed for predicting prodromal and early PD. The nomogram is easy to utilize in a clinical setting since it consists of age, gender, education level, and transcriptional score (calculated by 10 miRNA profiles). Compared with the independent clinical model or 10 miRNA panel separately, the nomogram was reliable and satisfactory because the area under the ROC curve achieved 0.72 (95% confidence interval, 0.68-0.77) and obtained a superior clinical net benefit in DCA based on external datasets. Moreover, calibration curves also revealed its excellent prediction power.

Conclusion: The constructed nomogram has potential for large-scale early screening of PD based upon its utility and precision.

References
1.
Chen J, Shen S, Li Y, Fan J, Xiong S, Xu J . APOLLO: An accurate and independently validated prediction model of lower-grade gliomas overall survival and a comparative study of model performance. EBioMedicine. 2022; 79:104007. PMC: 9035655. DOI: 10.1016/j.ebiom.2022.104007. View

2.
Latourelle J, Beste M, Hadzi T, Miller R, Oppenheim J, Valko M . Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation. Lancet Neurol. 2017; 16(11):908-916. PMC: 5693218. DOI: 10.1016/S1474-4422(17)30328-9. View

3.
Mehdi S, Rosas-Hernandez H, Cuevas E, Lantz S, Barger S, Sarkar S . Protein Kinases and Parkinson's Disease. Int J Mol Sci. 2016; 17(9). PMC: 5037850. DOI: 10.3390/ijms17091585. View

4.
Navarro M, Cantrell D . Serine-threonine kinases in TCR signaling. Nat Immunol. 2014; 15(9):808-14. PMC: 6443032. DOI: 10.1038/ni.2941. View

5.
Steyerberg E, Vergouwe Y . Towards better clinical prediction models: seven steps for development and an ABCD for validation. Eur Heart J. 2014; 35(29):1925-31. PMC: 4155437. DOI: 10.1093/eurheartj/ehu207. View